Business
ALX Oncology is a clinical-stage biotechnology company developing cancer therapies, including the CD47 blocker evorpacept and the EGFR-targeted antibody drug candidate ALX2004.
ALX Oncology had no revenue tagged in FY2025, but net loss narrowed to $101.7M and cash burn improved.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage cancer therapiesNote
- Revenue — No revenue tagged in FY2025Note
- Profitability — Net loss narrowed to $101.7MNote
- Cash — Free cash flow was negative $84.4MNote
- Equity — Equity fell 77.1%Watch
- Insiders — 4 buys / 6 sellsNote
- Accounting — No FY2025 forensic screenNote
Leadership changes
From ALX ONCOLOGY HOLDINGS INC's own filings, the day they're filed.
- Corey Goodman · Chairman · departureeff. 2026-06-29
- Jeff Knight · President · appointmenteff. 2026-04-13
- Harish Shantharam · Chief Financial Officer · appointmenteff. 2025-01-21
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALX ONCOLOGY HOLDINGS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.